选择性5-羟色胺再摄取抑制剂、文拉法辛与米氮平治疗重性抑郁的最优剂量:系统综述与剂量-反应荟萃分析
结果显示SSRIs在氟西汀等效20-40 mg时达到疗效与可接受性的最佳平衡,文拉法辛约75-150 mg、米氮平约30 mg时疗效最优,高于此范围疗效不再增加甚至下降。
要点
- SSRIs在氟西汀等效20-40 mg剂量范围内疗效随剂量增加,可接受性最佳。
- SSRIs因不良反应导致的脱落随剂量增加而陡增,高剂量耐受性差。
- 文拉法辛约75-150 mg、米氮平约30 mg时疗效最优,更高剂量疗效增加有限或下降。
核心结论
- 对于最常用的第二代抗抑郁药,许可剂量的较低范围在重性抑郁急性治疗中实现了疗效、耐受性与可接受性的最佳平衡。
研究设计与样本
- 检索截至2016年1月8日,无语言限制,排除伴有严重躯体共病的抑郁患者试验。
- 主要结局为疗效(治疗反应定义为抑郁严重度降低≥50%)、耐受性(因不良反应脱落)和可接受性(任何原因脱落),中位治疗8周(范围4-12周)。
主要发现
- SSRIs(99个治疗组)的剂量-疗效曲线在氟西汀等效20-40 mg内逐渐上升,至80 mg范围内呈平台或下降趋势。
- SSRIs因不良反应脱落随剂量增加而陡增;任何原因脱落在氟西汀等效20-40 mg较低许可范围内显示最佳可接受性。
- 文拉法辛(16个治疗组)剂量-疗效关系在约75-150 mg内初始增加,之后增加较温和;米氮平(11个治疗组)疗效增至约30 mg后下降。
- 文拉法辛和米氮平均在其许可剂量较低范围内显示最佳可接受性,结果经多项敏感性分析稳健。
关键数值与推荐
- SSRIs疗效在氟西汀等效20-40 mg内逐渐增加,至80 mg范围内平台或下降。
- SSRIs因不良反应脱落随剂量增加而陡增,任何原因脱落在氟西汀等效20-40 mg范围内最佳。
- 文拉法辛疗效在约75-150 mg内初始增加,之后增加较温和;米氮平疗效增至约30 mg后下降。
- 文拉法辛和米氮平均在许可剂量较低范围内显示最佳可接受性。
临床怎么用
- 处方SSRIs时优先考虑氟西汀等效20-40 mg的较低许可剂量范围以平衡疗效与耐受性。
- 文拉法辛考虑约75-150 mg、米氮平考虑约30 mg作为疗效最优剂量参考。
- 高于上述范围增加剂量时需权衡疗效增加有限与脱落风险升高的可能。
局限性
- 仅纳入固定剂量双盲随机对照试验,排除伴有严重躯体共病的抑郁患者。
- 主要结局评估时间为中位8周(范围4-12周),未涵盖长期治疗。
- 检索截至2016年1月8日,未纳入此后发表的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Depression is the single largest contributor to non-fatal health loss worldwide. Second-generation antidepressants are the first-line option for pharmacological management of depression. Optimising their use is crucial in reducing the burden of depression; however, debate about their dose dependency and their optimal target dose is ongoing. We have aimed to summarise the currently available best evidence to inform this clinical question. METHODS: We did a systematic review and dose-response meta-analysis of double-blind, randomised controlled trials that examined fixed doses of five selective serotonin reuptake inhibitors (SSRIs; citalopram, escitalopram, fluoxetine, paroxetine, and sertraline), venlafaxine, or mirtazapine in the acute treatment of adults (aged 18 years or older) with major depression, identified from the Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS, MEDLINE, PsycINFO, AMED, PSYNDEX, websites of drug licensing agencies and pharmaceutical companies, and trial registries. We imposed no language restrictions, and the search was updated until Jan 8, 2016. Doses of SSRIs were converted to fluoxetine equivalents. Trials of antidepressants for patients with depression and a serious concomitant physical illness were excluded. The main outcomes were efficacy (treatment response defined as 50% or greater reduction in depression severity), tolerability (dropouts due to adverse effects), and acceptability (dropouts for any reasons), all after a median of 8 weeks of treatment (range 4-12 weeks). We used a random-effects, dose-response meta-analysis model with flexible splines for SSRIs, venlafaxine, and mirtazapine. FINDINGS: 28 554 records were identified through our search (24 524 published and 4030 unpublished records). 561 published and 121 unpublished full-text records were assessed for eligibility, and 77 studies were included (19 364 participants; mean age 42·5 years, SD 11·0; 7156 [60·9%] of 11 749 reported were women). For SSRIs (99 treatment groups), the dose-efficacy curve showed a gradual increase up to doses between 20 mg and 40 mg fluoxetine equivalents, and a flat to decreasing trend through the higher licensed doses up to 80 mg fluoxetine equivalents. Dropouts due to adverse effects increased steeply through the examined range. The relationship between the dose and dropouts for any reason indicated optimal acceptability for the SSRIs in the lower licensed range between 20 mg and 40 mg fluoxetine equivalents. Venlafaxine (16 treatment groups) had an initially increasing dose-efficacy relationship up to around 75-150 mg, followed by a more modest increase, whereas for mirtazapine (11 treatment groups) efficacy increased up to a dose of about 30 mg and then decreased. Both venlafaxine and mirtazapine showed optimal acceptability in the lower range of their licensed dose. These results were robust to several sensitivity analyses. INTERPRETATION: For the most commonly used second-generation antidepressants, the lower range of the licensed dose achieves the optimal balance between efficacy, tolerability, and acceptability in the acute treatment of major depression. FUNDING: Japan Society for the Promotion of Science, Swiss National Science Foundation, and National Institute for Health Research.
引用
- Furukawa TA, Cipriani A, Cowen PJ, et al. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019. PMID: 31178367. doi:10.1016/S2215-0366(19)30217-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。